Meningococcal ACWY Conjugate vaccine
Meningococcal ACWY Conjugate vaccine is a biological therapy with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Clinical Trials (5)
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5